Congratulations to Thomas Hanff, MD, MSCE, MPH, Assistant Professor in the Division of Cardiovascular Medicine, on receiving a prestigious NIH award for his project, “Role of Angiotensin II in Cardiogenic Shock Pathophysiology and Outcomes.”

This grant supports Dr. Hanff’s research into improving the understanding and treatment of cardiogenic shock—a life-threatening condition requiring precise, individualized therapies. His research program will utilize a multicenter prospective cohort called VANQUISH SHOCK to advance our understanding of renin-angiotensin-aldosterone system changes in cardiogenic shock and the cardiorenal syndrome, in close collaboration with the new Cardio-Renal and Metabolism Center. Ultimately, the goal of this research is to uncover novel pathophysiologic mechanisms that can be targeted in future clinical trials to improve cardiogenic shock outcomes as a stand-alone therapy or adjunct therapy to temporary mechanical circulatory support.

Dr. Hanff is a board-certified cardiologist with specialized expertise in advanced heart failure, mechanical circulatory support, and transplant cardiology. He holds master’s degrees in public health as well as clinical epidemiology, with a focus on causal inference and advanced statistical modeling techniques. He joined the University of Utah in 2021, where he continues to practice at the forefront of evidence-based cardiovascular care. He is a nationally recognized expert in advanced heart failure and mechanical circulatory support. He is mentored by Drs. Stavros Drakos and Jamie Dwyer.

Research reported in this publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number K23HL175226. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.